Global Asthma Spacers Market – Industry Trends and Forecast to 2031

Asthma Spacers Market Analysis and Size

The COVID-19 crisis has accelerated the growth of the asthma spacers market, with increased demand due to the rising number of COVID-19 cases with respiratory symptoms and the high risk for people with asthma. Regulatory agencies are taking steps to ensure the availability of essential medical devices, including reducing import limits and expediting registration processes. Awareness programs and well-coordinated asthma management programs are also expected to drive market growth globally.

According to the Asthma and Allergy Foundation of America (AAFA), over 25 million Americans were affected by asthma in 2020. In 2019, approximately 20 million U.S. adults aged 18 and older had asthma. On average, asthma claimed the lives of 11 individuals in the U.S. each day. In 2020, 4,145 people died from asthma, according to the same source. These deaths could have been prevented with proper treatment and care. Individuals with asthma may require daily inhaler use. A spacer device facilitates using an aerosol inhaler and ensures that the medication reaches the lungs more effectively.

Data Bridge Market Research analyses that the Asthma Spacers market which was USD 1,788.60 million in 2023, would rocket up to USD 2,508.73 million by 2031, and is expected to undergo a CAGR of 4.32% during the forecast period. This indicates the market value. “Anti-inflammatory” dominates the drug class segment of the Asthma Spacers market owing to widespread use in managing asthma, which often involves reducing airway inflammation and preventing asthma symptoms. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Asthma spacers, inhaler spacers, or aerosol-holding chambers are devices used with Metered-Dose Inhalers (MDIs) to improve medication delivery into the lungs. They help overcome some of the challenges associated with using MDIs correctly, such as coordinating inhalation timing with the inhaler's activation. Spacers hold the medication released from the inhaler, allowing the individual to inhale the medication more slowly and deeply, ensuring more of the medication reaches the lungs. They also reduce the risk of side effects by decreasing the amount of medication deposited in the mouth and throat. The increasing prevalence of asthma worldwide, which is leading to a greater demand for effective asthma management devices, including spacers, is the major driving factor in the market

Global Asthma Spacers Market Dynamics

Drivers

• Increasing Prevalence of Asthma

The increasing prevalence of asthma globally is a significant driver of the asthma spacers market. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath. As the number of people with asthma grows, so does the demand for effective asthma management devices, such as spacers. Asthma spacers are crucial in delivering medication effectively to the lungs, particularly with Metered-Dose Inhalers (MDIs). Spacers act as an intermediary device that holds the medication released from the inhaler, allowing the individual to inhale the medication more slowly and deeply. This ensures that more medication reaches the lungs, improving treatment outcomes for asthma patients.

Moreover, asthma spacers help overcome some of the difficulties associated with using MDIs correctly, such as coordinating inhalation timing with the inhaler's activation. They also reduce the risk of side effects by decreasing the amount of medication deposited in the mouth and throat, making them particularly beneficial for children and elderly patients.

• Growing Focus on Preventive Healthcare

The healthcare prospect is witnessing a notable shift towards preventive healthcare, with an increasing emphasis on managing chronic conditions like asthma before they escalate into serious health issues. This change is driven by recognizing that preventive measures can significantly improve health outcomes and reduce healthcare costs in the long run. As part of this trend, there is a growing focus on comprehensive asthma management programs that aim to treat symptoms and prevent asthma attacks.

A key component of these programs is asthma spacers, which play a crucial role in ensuring the effective delivery of medication to the lungs. By using spacers with metered-dose inhalers (MDIs), patients can inhale the medication more effectively, leading to better control of their asthma symptoms. This, in turn, can help reduce the frequency and severity of asthma attacks, improving asthma patients' overall quality of life. Healthcare providers increasingly include asthma spacers in asthma management plans, recognizing their importance in achieving optimal treatment outcomes. Patients are also becoming more aware of the benefits of spacers and are more likely to adhere to their treatment regimen when they are included.

Opportunities

• Increasing Adoption in Emerging Markets

In some regions, there may be limited awareness about the benefits of using asthma spacers among healthcare providers and patients. In addition, accessibility to asthma spacers may be limited in certain areas, especially in low-income regions or rural areas. This lack of awareness and accessibility can hinder market growth as it may result in lower adoption rates of asthma spacers.

• Technological Advancements and Product Innovation

There is scope for technological advancements and product innovation in the asthma spacers market. Manufacturers can develop spacers with improved features such as dose counters, anti-static properties, and smaller, more portable designs. In addition, advancements in materials and manufacturing processes can lead to more cost-effective and user-friendly spacers. These innovations can help influence market growth by improving the usability and effectiveness of asthma spacers, leading to increased adoption among patients and healthcare providers.

Restraints/Challenges

• Limited Awareness and Accessibility

Prolonged or frequent use of antiviral drugs can lead to the development of resistance, where the virus becomes less responsive to treatment. This can limit the effectiveness of existing medications and pose challenges in managing Asthma Spacers infections, particularly in individuals who require long-term treatment. The emergence of antiviral resistance highlights the need for continued research and development of new treatment options to combat resistant strains of the virus.

• Competition from Alternative Devices

Asthma spacers face competition from alternative devices, such as nebulizers and Dry Powder Inhalers (DPIs), which also deliver asthma medication. Some patients or healthcare providers may prefer these alternative devices, leading to a fragmented market and increased competition for asthma spacers. Manufacturers of asthma spacers must differentiate their products and demonstrate their advantages over alternative devices to maintain market share.

This global asthma spacers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asthma Spacers market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In January 2022, Monaghan Medical Corporation (MMC) was honored with the 2021 Zenith Award by the American Association for Respiratory Care (AARC), marking the seventh consecutive year that MMC has received this prestigious recognition. MMC is a leader in the development, manufacture, and marketing of respiratory devices, including the AeroChamber Plus, Flow-Vu VHC, AeroEclipse II Nebulizer, and Aerobika Oscillatory Pep Device

Global Asthma Spacers Market Scope

The global asthma spacers market is segmented on the basis of drug class, product type, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Anti-inflammatory
• Bronchodilators
• Combination Therapy

Product Type

• Inhalers
  • Dry Powder
  • Metered Dose
  • Soft Mist
• Nebulizers

Route of Administration

• Oral
• Inhaled
• Others

Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

Global Asthma Spacers Market Regional Analysis/Insights

The global Asthma Spacers market is analyzed and market size insights and trends are provided by country, drug class, product type, route of administration, and distribution channel as referenced above.

The countries covered in the Asthma Spacers market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

North America is expected to dominate the market due to the high prevalence of asthma in the region, a well-established healthcare infrastructure, and a high level of awareness about asthma management among healthcare providers and patients.

Asia-Pacific is expected to grow significantly due to factors such as air pollution, urbanization, and changing lifestyles.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global asthma spacers market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Asthma Spacers market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market.

Competitive Landscape and Asthma Spacers Market Share Analysis

The global asthma spacers market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the global asthma spacers market are:

• Teva Pharmaceutical Industries Ltd (Israel)
• GSK plc (United Kingdom)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• AstraZeneca (United Kingdom)
• Boehringer Ingelheim International GmbH (Germany)
• Sanofi (France)
• Koninklijke Philips N.V. (Netherlands)
• BD (U.S.)

SKU-70708